^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PGR (Progesterone receptor)

    i
    Other names: PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
    1d
    A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) (clinicaltrials.gov)
    P3, N=541, Active, not recruiting, DualityBio Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • mTOR (Mechanistic target of rapamycin kinase)
    |
    HER-2 positive • HER-2 expression • HER-2 underexpression
    |
    capecitabine • albumin-bound paclitaxel • trastuzumab pamirtecan (BNT323)
    1d
    Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer (clinicaltrials.gov)
    P2, N=68, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    carboplatin • albumin-bound paclitaxel • Zolinza (vorinostat)
    1d
    Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer (clinicaltrials.gov)
    P=N/A, N=350, Suspended, City of Hope Medical Center | Initiation date: Jan 2026 --> May 2026
    Trial initiation date • Minimal residual disease • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    2d
    Basaloid-Solid Adenoid Cystic Carcinoma of the Breast: A Case Report and Literature Review. (PubMed, Case Rep Pathol)
    At 12-month follow-up, local recurrence and bilateral axillary metastases were identified. This case emphasizes the diagnostic challenge of SB-AdCC, its overlap with basaloid carcinoma, and the importance of recognizing its distinct morphological and molecular features.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • TP63 (Tumor protein 63)
    2d
    Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov)
    P3, N=5018, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2032 --> Jan 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Oncotype DX Breast Recurrence Score®Test
    |
    letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    2d
    The LYSA (Linking You to Support and Advice) Trial (clinicaltrials.gov)
    P=N/A, N=200, Completed, University College Cork | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Mar 2026
    Trial completion • Trial completion date • HEOR
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative
    2d
    MINA: Microbiome Immunotherapy Neoadjuvant Assessment (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, University College Cork | Trial completion date: Feb 2027 --> Nov 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    PD-L1 IHC 22C3 pharmDx
    3d
    Overexpression of TFF3 is Associated with Immune Infiltration, Molecular Subtypes, and Clinical Progression in Breast Cancer. (PubMed, Curr Med Sci)
    TFF3 is a robust diagnostic biomarker for BRCA molecular subtyping, an independent prognostic factor, and a potential immunomodulator. These findings highlight its clinical utility for patient stratification and potential as a therapeutic target, particularly in hormone receptor-positive BRCA.
    Journal • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • BRCA (Breast cancer early onset) • TFF3 (Trefoil factor 3)
    |
    HR positive
    3d
    Materials-Driven Fluorescent Sensor Array of Dye-Derived Carbon Dots for Sensitive Detection of Multiple Proteins and the Cancer Biomarker Progesterone Receptor Membrane Component-1. (PubMed, Anal Chem)
    Fluorescence lifetime analysis combined with density functional theory calculations elucidated the underlying mechanism of interaction between the CDs and proteins, highlighting the contribution of precursor-dependent surface states. This study introduces a new design paradigm for CD-based fluorescent arrays and showcases their strong promise for complex biological analysis, precision biomarker detection, and clinical diagnostics.
    Journal
    |
    PGR (Progesterone receptor)
    3d
    LUBRECA: Luminal Breast Cancer Cryoablation (clinicaltrials.gov)
    P=N/A, N=140, Recruiting, Lucía Graña López
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR positive
    3d
    Study on the Safety and Tolerability of Postoperative Radiotherapy Concurrent With CDK4/6 Inhibitors in HR+/HER2- High-Risk Breast Cancer (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Guizhou Provincial People's Hospital
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    3d
    Pilot Study of Aerobic Exercise During Immune Checkpoint Inhibitor Therapy in Early-Stage TNBC (clinicaltrials.gov)
    P=N/A, N=33, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative